Jaguar Health’s Napo Pharma Satisfies Conditions Required To Receive Payment Of Non-Dilutive $2M Holdback Amount From Future Pak Related To US Commercial Licensing Agreement

Loading news article.

Jaguar Health’s Napo Pharma Satisfies Conditions Required To Receive Payment Of Non-Dilutive $2M Holdback Amount From Future Pak Related To US Commercial Licensing Agreement | WAPE

Jaguar Health’s Napo Pharma Satisfies Conditions Required To Receive Payment Of Non-Dilutive $2M Holdback Amount From Future Pak Related To US Commercial Licensing Agreement

Article summary

Related companies

Comments —